Search

Selpercatinib (also known as LOXO-292) is a highly selective RET inhibitor with activity against diverse RET fusions, activating RET mutations and brain metastasis. Phase 1/2 data from the LIBRETTO-001 trial presented at the IASLC 2019 World Conference on Lung Cancer demonstrates selpercatinib’s marked antitumor activity in RET fusion-position non-small cell lung cancer (NSCLC) patients. These findings, presented by Alexander Drilon, MD, principal investigator and Research Director of Early Drug Development at Memorial Sloan Kettering Cancer Center, will form the basis of an US Food and Drug Administration new drug application submission.

… Monday, September 9, 2019 Bottom Line: Selpercatinib (also known as LOXO-292) is a highly selective RET inhibitor with activity against diverse RET fusions, activating RET mutations and brain metastasis. Phase 1/2 data from the LIBRETTO-001 trial presented at the IASLC 2019 World Conference on Lung Cancer

The Gene: An Intimate History is a new four-hour documentary from the award-winning Ken Burns team and PBS, adapted from the award-winning book of the same name by Siddhartha Mukherjee, MD, DPhil. Memorial Sloan Kettering’s Luis Alberto Diaz, Jr., MD, Head of the Division of Solid Tumor Oncology, is a featured expert.

… Monday, April 13, 2020 The Gene: An Intimate History is a new four-hour documentary from the award-winning Ken Burns team and PBS, adapted from the award-winning book of the same name by Siddhartha Mukherjee, MD, DPhil. The two-part series brings to life a historical biography of the human genome while

All radiotherapy treatments for prostate cancer should be accompanied by image-guidance of the prostate position to rule out significant setup errors in fractional delivery.

… Monday, November 19, 2018 All radiotherapy treatments for prostate cancer should be accompanied by image-guidance of the prostate position to rule out significant setup errors in fractional delivery. The results of our most recent analysis of planning data for 102 patients treated consecutively at Memorial

Memorial Sloan Kettering's Boards of Overseers and Managers have announced the creation of the Bristol-Myers Squibb/James D. Robinson III Junior Faculty Chairs and have named the first two incumbents: Sloan Kettering Institute's Grégoire Altan-Bonnet and Songhai Shi.

… Wednesday, July 1, 2009 Summary Memorial Sloan Kettering’s Boards of Overseers and Managers have announced the creation of the Bristol-Myers Squibb/James D. Robinson III Junior Faculty Chairs and have named the first two incumbents: Sloan Kettering Institute’s Grégoire Altan-Bonnet and Songhai Shi. Memorial

James Rothman, who receives this year’s Nobel Prize in Physiology or Medicine together with Randy Schekman and Thomas Südhof, conducted more than a decade of his seminal research at Memorial Sloan Kettering.

… Monday, October 14, 2013 Summary James Rothman, who receives this year’s Nobel Prize in Physiology or Medicine together with Randy Schekman and Thomas Südhof, conducted more than a decade of his seminal research at Memorial Sloan Kettering. Last week James E. Rothman, Randy W. Schekman, and Thomas C.

Meet Mary Wu, a patient financial services specialist at Memorial Sloan Kettering Westchester.

… Tuesday, May 17, 2022 Mary Wu remembers the 2012 Rose Parade like it was yesterday. The roar of the spectators lining Colorado Boulevard as each float came into view. The warmth of the New Year’s Day sun. Her perch atop the Donate Life Float . “I can’t put it into words,” says Mary, a patient financial

MSK researchers have found that a genetic state in tumors called whole-genome doubling is connected with worse outcomes for people with cancer.

… Wednesday, July 18, 2018 Summary MSK-IMPACT™ has led to many important findings about cancer genomics. In a recent study, researchers found that a genetic state in tumors called whole-genome doubling is connected with worse outcomes for people with cancer. Healthy cells contain two copies of each gene

New research on an experimental drug provides hope for better responses to immunotherapy.

… Wednesday, November 9, 2016 Summary Despite the promise of immunotherapy for cancer, not everyone responds. Researchers at MSK are testing a new drug that can overcome a tumor’s resistance to immunotherapy. Highlights Many tumors contain immune-suppressive cells that make them resistant to immunotherapy

Memorial Sloan Kettering Cancer Center will recognize three young investigators for their exceptional bodies of innovative work that has helped to advance the field of cancer research. The researchers will receive the Paul Marks Prize for Cancer Research, an award presented biennially by Memorial Sloan Kettering to honor promising scientists under the age of 46.

… Tuesday, September 20, 2011 Memorial Sloan Kettering Cancer Center will recognize three young investigators for their exceptional bodies of innovative work that has helped to advance the field of cancer research. The researchers will receive the Paul Marks Prize for Cancer Research, an award presented

Uniting MSK’s research and clinical expertise with AWS’s advanced cloud technologies is a bold step towards addressing one of the world’s most pressing health challenges.

… Monday, March 10, 2025 Amazon Web Services (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN) and Memorial Sloan Kettering Cancer Center (MSK), a leading global cancer center, today announced a collaboration harnessing the power of artificial intelligence (AI), high performance computing (HPC), and other